Document is current
Any future updates will be listed below
-
Authors
Bolis, Marco https://orcid.org/0000-0003-4377-5079
Bossi, Daniela
Vallerga, Arianna
Ceserani, Valentina
Cavalli, Manuela
Impellizzieri, Daniela
Di Rito, Laura
Zoni, Eugenio
Mosole, Simone
Elia, Angela Rita
Rinaldi, Andrea
Pereira Mestre, Ricardo https://orcid.org/0000-0002-3123-3697
D’Antonio, Eugenia https://orcid.org/0000-0003-1248-1668
Ferrari, Matteo
Stoffel, Flavio
Jermini, Fernando
Gillessen, Silke
Bubendorf, Lukas https://orcid.org/0000-0001-5970-1803
Schraml, Peter
Calcinotto, Arianna https://orcid.org/0000-0003-1746-6424
Corey, Eva
Moch, Holger https://orcid.org/0000-0002-7986-2839
Spahn, Martin
Thalmann, George
Kruithof-de Julio, Marianna https://orcid.org/0000-0002-6085-7706
Rubin, Mark A. https://orcid.org/0000-0002-8321-9950
Theurillat, Jean-Philippe P. https://orcid.org/0000-0003-0111-5937
- License Information
-
More Information
Article History
Received: 4 March 2021
Accepted: 20 October 2021
First Online: 2 December 2021
Change Date: 19 June 2025
Change Type: Update
Change Details: Following publication of this article, the link to the PCaProfiler interface for the Prostate Cancer Transcriptome Atlas has been updated to https://www.prostatecanceratlas.org/. The link is updated in the HTML and PDF versions of the article.
Competing interests
: M.A.R. is listed as a co-inventor on the US and International patents in the diagnostic and therapeutic fields of ETS gene fusion prostate cancers (Harvard and the University of Michigan) and SPOP mutations (Weill Cornell Medicine). J.-P.P.T. has received funding for the venue of scientific conferences from Astellas, MSD, and Janssen/Cilag. S.G. (past 3 years): honoraria—Janssen Cilag; consulting or advisory role (including IDMC)—Astellas Pharma, Amgen, Roche, Pfizer, AAA International, Janssen, Innocrin Pharma Inst, Sanofi, Bayer, Orion Pharma GmbH, Clovis Oncology, Menarini Silicon Biosystems, Tolero Pharmaceuticals, and MSD; patents, royalties, and other intellectual property—method for biomarker WO2009138392; travel grant—ProteoMediX; other relationship—Aranda. The remaining authors declare no competing interests.
